Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance
therapy is the latest breakthrough in the management of
newly diagnosed advanced ovarian cancer. The results
of the SOLO-1 trial in 2018 led to European Medicines
Agency and Food and Drug Administration approval of
olaparib as first-line maintenance therapy in patients with
BRCA1/2 mutation, establishing a new standard of care.
Subsequently, the results of three phase III trials (PRIMA,
PAOLA-1, VELIA) evaluating the use of first-line PARP
inhibitors beyond patients with BRCA1/2 mutations and as
combination strategies were presented in 2019, leading to
the recent approval of maintenance niraparib irrespective
of biomarker status and olaparib in combination with
bevacizumab in homologous recombination deficiencypositive-associated advanced ovarian cancer. An ESMO
Open - Cancer Horizons round-table expert panel
discussed the four phase III trials of first-line PARP
inhibitor therapy and how they are changing the clinical
management of advanced ovarian cancer